WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > ViMedicus
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Sestina Bio | October 17, 2020
Sestina Bio, a new company creating a platform for automated synthetic biology, today announced that it has launched with seed funding from Foresite Capital, General Inception and OMX Ventures. The funds will be used to further the development of its digital cellular engineering and phenotyping platforms and support initial product development. The firm is the first company to launch from incubator Foresite Labs. Practitioners of synthetic biology aim to engineer novel living organisms -- usuall...
Industrial Impact
ProPhase Labs, Inc. | June 29, 2022
ProPhase Labs, Inc., a diversified biotech, genomics, and diagnostics company manufacturing homeopathic and health products, announced the formation of a new wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), for the development and licensing of new therapeutic compounds, drugs, and biotechnology. The subsidiary will be focused on advancements in technology across the biochemical industry and creating and developing new solutions that can transform the outcomes of healthcare. Read More
Cell and Gene Therapy
c-LEcta | December 20, 2021
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...
MedTech
Neumora | October 12, 2022
Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...
Medical
Whitepaper
Research, Medical
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE